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Acute HIV Infection and CD4/CD8 Ratio Normalization
After Antiretroviral Therapy Initiation
Thibaut Davy-Mendez, MSPH,* Sonia Napravnik, PhD,* Oksana Zakharova, MS,*
JoAnn Kuruc, MSN, RN,* Cynthia Gay, MD, MPH,* Charles B. Hicks, MD,†
Kara S. Mcgee, MSPH, PA-C,‡ and Joseph J. Eron, MD*
Background: We estimated the effect of initiating virologically
suppressive antiretroviral therapy (ART) during acute HIV infection
versus chronic HIV infection (AHI vs. CHI) on CD4/CD8
ratio normalization.
Setting: A prospective clinical cohort study.
Methods: We included patients initiating ART with AHI and CHI
between 2000 and 2015 and compared time from ART initiation to
the first normal CD4/CD8 ratio (defined as CD4/CD8 $1) using
Kaplan–Meier curves and multivariable Cox proportional hazards
models. Patient time was censored at virologic failure, lost to follow-
up, or death. We also characterized CD4, CD8, and CD4/CD8
trajectories over the first 3 years of ART.
Results: The 1198 patients were 27% female and 60% African
American, with a median age of 37 years (interquartile range 28–47)
at ART initiation. The 83 AHI patients were more likely male,
younger, and of white race, than CHI patients. After 2 years of
suppressive ART, 70% of AHI patients achieved a normal CD4/CD8
ratio, compared to 6%–38% of CHI patients, with greater likelihood
of normalization at higher baseline CD4 counts. Time to normali-
zation was shortest among AHI patients, followed by CHI patients
with higher baseline CD4. The adjusted hazard ratio for time to
normalization for AHI patients compared to CHI patients with
baseline CD4 .350 was 4.33 (95% CI: 3.16 to 5.93). Higher
baseline CD4/CD8 ratio was also associated with time to normal-
ization (adjusted hazard ratio 1.54; 1.46, 1.63, per 0.1 increase
in ratio).
Conclusions: Initiating ART during AHI at higher baseline CD4
cell counts and CD4/CD8 ratios was associated with shorter time to
CD4/CD8 ratio normalization.
Key Words: HIV, anti-HIV agents, CD4-CD8 ratio, inflammation,
acute retroviral syndrome
(J Acquir Immune Defic Syndr 2018;79:510–518)
INTRODUCTION
Despite effective antiretroviral therapy (ART), persons
living with HIV (PLWH), compared with HIV-uninfected
persons, experience a higher incidence of non–AIDS-related
morbidities, such as advanced cardiovascular disease and
many types of malignancies.1–4 The life expectancy of PLWH
receiving ART is also persistently lower than that for HIV-
uninfected populations in some regions of the world and for
patients with poor immune response.5–8 These differences
likely have multiple causes including lifestyle factors, viral
coinfections, as well as persistent immune dysfunction due to
HIV.9–12 Chronic immune activation and inflammation
leading to immunosenescence are associated with morbidity
and mortality, and biomarkers of activation and inflammation
remain higher among PLWH after years on effective
ART.12–14 A CD4/CD8 ratio ,1 is associated with bio-
markers of activation and inflammation and is predictive of
non–AIDS-related morbidity and mortality.15–19 The CD4/
CD8 ratio should therefore be considered as a potential
marker for measuring the success of treatment strategies that
limit persistent inflammation.
Initiating ART early in HIV infection improves clinical
outcomes.20 ART started during acute HIV infection (AHI)
rapidly suppresses HIV replication and increases the recovery
of CD4 cell counts, and may prevent persistent immune
activation and inflammation.21–24 However, few studies have
investigated the evolution of CD4/CD8 ratios longitudinally
in the clinical setting or examined CD4/CD8 ratios in patients
initiating ART close to infection. We estimated the effect of
initiating ART during AHI versus chronic HIV infection
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comparability with previous CD4/CD8 normalization studies.
We compared all AHI patients to CHI patients categorized by
CD4 count at baseline:,200, 200–350, and.350 cells/mm3.
Patients were censored at the earliest of: death; virologic
failure, defined as the first of 2 consecutive viral loads $400
copies/mL at least 30 days apart 24 weeks after baseline; loss
to follow-up, defined as 1 year after the last HIV clinic or
laboratory visit); or administrative censoring on December
31, 2015. We examined trajectories of CD4 counts, CD8
counts, and CD4/CD8 ratios in 3-month intervals for 3 years
after baseline, including the closest laboratory measurement
within 45 days of each time point.
Statistical Analyses
Chi-square and Kruskal–Wallis tests compared AHI
and CHI patients’ baseline characteristics. We performed
time-to-event analyses using Kaplan–Meier curves with log-
rank tests, and Cox proportional hazards models to estimate
hazard ratios (HRs) and 95% confidence intervals, adjusting
for baseline CD4/CD8 ratio, sex, race/ethnicity, and age.
Analyses were stratified by AHI and CHI categories as well as
baseline CD4/CD8 ratios, using tertiles of AHI patients’
baseline CD4/CD8 ratio distribution. Distributions of CD4
and CD8 cell counts and CD4/CD8 ratios were compared
between groups using Wilcoxon rank–sum tests at months 0,
3, 9, 12, 24, and 36 after baseline, censoring patients after
virologic failure.
In primary analyses, we excluded patients who were
missing baseline CD4/CD8 ratio (n = 115), did not have any
CD4/CD8 ratio measured during the study period (n = 57),
and had a normal baseline ratio (n = 12 AHI patients and 38
(CHI) on CD4/CD8 ratio recovery. We also characterized 
trajectories of CD4 cells, CD8 cells, and the CD4/CD8 ratio 
after ART initiation among both AHI and CHI patients.
METHODS
Study Population
Patients were drawn from the University of North 
Carolina (UNC) Center for AIDS Research HIV Clinical 
Cohort (UCHCC), a prospective clinical cohort of primary 
HIV care patients at UNC hospitals since 1996,25 and from 
the Duke-UNC Acute HIV Cohort, which includes HIV-
infected individuals referred to UNC or Duke Hospital with 
either a negative or indeterminate antibody test and repro-
ducibly detectable HIV RNA, or a positive antibody test with 
seronegative documentation in the previous 30 days.21 The 
AHI group included acute HIV cohort participants who 
initiated ART between January 1, 2000, and December 31, 
2015, ,120 days after estimated infection date, calculated as 
14 days before acute retroviral syndrome onset (Fig. 1).21 The 
CHI group included UCHCC participants with no record of 
acute retroviral syndrome who initiated ART in the same 
calendar period. UNC’s Institutional Review Board approved 
this study, and patients provided written informed consent.
Outcomes
We examined time from ART initiation (baseline) to 
CD4/CD8 ratio normalization, defined as the first CD4/CD8 
ratio $1. We chose this definition because a ratio ,1 is  
associated with immune dysfunction markers15 and for
FIGURE 1. Flow diagram of patient inclusion
and exclusion for AHI (A) and CHI (B).
CHI patients) (Fig. 1). In secondary analyses, we included
patients with missing or normal baseline ratios. For patients
with missing CD4 or CD4/CD8 ratio at baseline, we used
multiple imputation with 50 imputations and a single Markov
chain, based on AHI status, sex, race/ethnicity, age, MSM,
and baseline log10 HIV RNA. P values were 2-sided and
,0.05 was considered statistically significant. SAS software,
version 9.4 (Cary, NC), was used for all analyses.
RESULTS
The 1198 included patients were 27% female, 60%
African American, 26% white, and 14% Hispanic or other
race/ethnicity, and they contributed a median follow-up time
of 4.6 years [interquartile range (IQR) 1.8–8.3] and a total of
6606 person-years. At baseline, the median (IQR) age was 37
years (28, 47), calendar year 2007 (IQR 2003, 2011), CD4
count 234 cells/mm3 (IQR 62–408), CD8 count 823 cells/
mm3 (IQR 510–1177), and CD4/CD8 ratio was 0.2 (IQR 0.1–
0.4). The 83 AHI patients (7%) were younger and more likely
to be male and white (all P , 0.05) (Table 1). Seventeen
percent of patients were censored at lost to follow-up, 23% at
virologic failure, and 6% at death, and these varied by AHI
and CHI categories, with CHI patients with CD4 ,200
having greater proportions of patients censored due to death
and virologic failure. AHI patients had a median of 13 (IQR
8–23) available CD4/CD8 ratio measurements with a median
interval of 2.5 months (IQR 0.9–3.4) between measurements.
CHI patients had a median of 15 (IQR 7–26) CD4/CD8 ratio
measurements with a median interval of 3.2 months (IQR
1.8–5.0) between measures. Among AHI patients, the median
time from estimated infection date to ART initiation was 43
days (IQR 35–58).
Time to CD4/CD8 Normalization
One year after baseline, 62% of AHI patients who
achieved and maintained virologic suppression had a normal
CD4/CD8 ratio, in contrast to 23%, 13%, and 2% of CHI
patients with baseline CD4 .350, 200–350, and ,200,
respectively (Fig. 2A, P , 0.05). After 2 years of ART and
remaining suppressed, these percentages rose to 70% among
AHI patients compared to 38%, 21%, and 6% for CHI
patients with baseline CD4 .350, 200–350, and ,200,
respectively. The median time to CD4/CD8 normalization
among AHI patients was 0.5 years, in contrast to 3.4 and 7.4
years among CHI patients with baseline CD4 .350 and 200–
350, respectively. After 14.3 years of follow-up, ,50% of
CHI patients with baseline CD4 ,200 had a normal ratio.
Further dividing patients into subgroups with baseline
ratio,0.3, 0.3–0.5, and 0.5–1.0, consistent with overall results
(Fig. 2A), we observed the most rapid CD4/CD8 normalization
among AHI patients in all subgroups (Fig. 2B–D, all
P , 0.05). Among both AHI and CHI patients, irrespective
of baseline CD4, subgroups with higher baseline CD4/CD8
ratios had shorter times to normalization than those with lower
baseline ratios (all P , 0.05). Comparing only CHI patients
with baseline CD4 200–350 to CHI with CD4 .350, we
TABLE 1. Demographic and Clinical Characteristics of Patients Initiating Antiretroviral Therapy, 2000–2015, Stratified by Acute
Versus Chronic HIV Infection and Baseline CD4 Cell Count
Characteristic Acute HIV Infection (N = 83)
Chronic HIV Infection
P*CD4 , 200 (N = 542) CD4 200–350 (N = 232) CD4 . 350 (N = 341)
Sex, n (%) ,0.05
Male 75 (90) 399 (74) 165 (71) 241 (71)
Female 8 (10) 143 (26) 67 (29) 100 (29)
Race/ethnicity, n (%) ,0.05
African American 48 (58) 324 (60) 134 (58) 211 (62)
White 28 (34) 130 (24) 58 (25) 98 (29)
Hispanic, any race 7 (8) 15 (3) 2 (1) 5 (1)
Other 0 (0) 73 (13) 38 (16) 27 (8)
Calendar year, median (IQR) 2009 (2007–2012) 2005 (2002–2009) 2007 (2004–2011) 2010 (2007–2013) ,0.05
Age, median years (IQR) 26 (23–38) 40 (33–48) 38 (28–47) 30 (25–40) ,0.05
CD4 count, median cells/mm3 (IQR)† 454 (338–587) 54 (17–122) 269 (239–307) 469 (403–590) ,0.05
CD8 count, median cells/mm3 (IQR)† 1142 (829–1531) 549 (318–842) 884 (602–1187) 1064 (841–1435) ,0.05
CD4/CD8, median (IQR)† 0.4 (0.2–0.6) 0.1 (0.1–0.2) 0.3 (0.2–0.5) 0.5 (0.4–0.6) ,0.05
HIV RNA, median log10 copies/mL
(IQR)†
5.2 (4.6–5.8) 5.3 (4.8–5.8) 4.6 (4.2–5.0) 4.3 (3.8–4.7) ,0.05
Follow-up time, total years 98 2119 679 736
Censored, n (%)
LTFU 14 (17) 98 (17) 49 (21) 53 (16)
VF 5 (6) 161 (30) 43 (19) 61 (18)
Death 0 (0) 60 (11) 8 (3) 1 (,1)
*P value comparing acute and chronic groups using Kruskal–Wallis test for continuous variables and Pearson x2 test for categorical variables.
†Laboratory measurements are the closest available measure in the year preceding ART initiation.
LTFU, loss to follow-up; VF, virologic failure.
Compared to CHI patients with baseline CD4 ,200, the
unadjusted HR was higher for CHI with higher CD4 counts
and for AHI patients (Table 2). In models partially adjusted
for age, sex, and race, HR estimates were similar. In fully
adjusted models also including baseline CD4/CD8 ratio,
baseline CD4 was not longer associated with time to nor-
malization in CHI patients, but AHI still had an HR of 5.05
(95% CI: 3.36 to 7.59) compared to CHI with CD4 ,200
(Table 2). In fully adjusted models, AHI had an HR of 4.43
(95% CI: 3.27 to 5.99) compared to all combined CHI, and
an HR of 4.33 (95% CI: 3.16 to 5.93) compared to CHI
with CD4 .350. Model estimates, both unadjusted and
adjusted, stratified by baseline CD4/CD8 ratio showed
similar differences in time to normalization between groups
as did stratified Kaplan–Meier curves (Supplemental Dig-
ital Content Table, http://links.lww.com/QAI/B209).
FIGURE 2. Time from ART initiation to CD4/CD8 ratio normalization stratified by AHI and CHI according to baseline CD4 cell
count, 2000–2015. Among (A) all patients (n = 1198); and patients with a baseline CD4/CD8 ratio (B),0.3 (n = 700); (C) 0.3–0.5
(n = 276); and (D) 0.5–1.0 (n = 222).
observed no difference in time to CD4/CD8 ratio normalization 
in ratio subgroup ,0.3 (8% vs. 8% normalized after 2 years, 
respectively, P = 0.53), subgroup 0.3–0.5 (24% vs. 30%, P = 
0.36), or subgroup 0.5–1.0 (50% vs. 57%, P = 0.92). In  
comparison to all CHI patients with baseline CD4 .200, CHI 
patients with CD4 ,200  seemed to take longer to achieve  
a normal CD4/CD8 ratio in the subgroup with baseline ratio of 
,0.3 (5% vs. 8% normalized after 2 years, P , 0.05). We did 
not compare to patients with baseline CD4 ,200 in other ratio 
subgroups because very few had a CD4/CD8 ratio 0.3–0.5 
(n = 29, 5%) or 0.5–1.0 (n = 6, 1%).
Unadjusted Cox model results for time to normalization 
were consistent with Kaplan–Meier curves, with an HR 
comparing AHI patients to all combined CHI patients of 5.69 
(95% CI: 4.30 to 7.53), and an HR comparing AHI patients to 
CHI with baseline CD4 .350 of 2.86 (95% CI: 2.1 to 3.87).
TABLE 2. Unadjusted and Adjusted Hazard Ratios and 95%
Confidence Intervals for Time to CD4/CD8 Ratio
Normalization
Parameter







CHI with CD4 ,200 1. (ref.) 1. (ref.) 1. (ref.)












































*Partially adjusted model includes all variables in table, measured at baseline,
except CD4/CD8 ratio.
†Fully adjusted model includes all variables in table, measured at baseline.
Baseline CD4/CD8 ratio was predictive of time to 
normalization in all models, with a fully adjusted HR of 1.54 
(95% CI: 1.46 to 1.63) per 0.1 ratio increase (Table 2). In both 
unadjusted and partially adjusted analyses, male sex was 
associated with a lower rate of normalization, but this was not 
statistically significant in the fully adjusted analyses that 
included both CHI CD4 categories and baseline CD4/CD8 
ratio (HR 0.82, 95% CI: 0.65 to 1.04). A 10-year increase in 
age was associated with lower normalization rates in the 
unadjusted model (HR 0.87, 95% CI: 0.79 to 0.95), but higher 
normalization rates in the fully adjusted model (HR 1.11, 
95% CI: 1.01 to 1.21). Race/ethnicity was not associated with 
time to normalization in unadjusted or adjusted analyses.
Sensitivity Analyses
In a sensitivity analysis also including patients with 
CD4/CD8 ratios $1 at baseline (n = 12 additional patients for 
AHI, n = 38 additional patients for CHI), after 2 years of ART 
and remaining suppressed, a total of 73% of AHI patients had 
a normal CD4/CD8 ratio, compared to 43%, 21%, and 6% for 
CHI with CD4 .350, 200–350, and ,200, respectively. In 
another sensitivity analysis using imputation for missing 
baseline laboratory values, in the fully adjusted model, age 
was no longer associated with time to CD4/CD8 
normalization (HR 1.06, 95% CI: 0.97 to 1.17), and CHI 
with CD4 .350 had a significantly shorter time to normal 
CD4/CD8 compared to CHI with CD4 ,200 (HR 1.53, 95%
CI: 1.09 to 2.14). Other associations remained unchanged. To 
explore whether natural CD4 and CD8 changes in AHI 
patients impacted CD4/CD8 normalization estimates, we 
conducted a subgroup analysis of patients without the
FIGURE 3. Median and IQRs of CD4 (A), CD8 (B), and CD4/
CD8 ratio (C) among AHI and CHI patients after antiretroviral 
therapy initiation, 2000–2015.
Although it is possible that a CD8 drop would occur naturally
after early AHI, 2 studies of untreated AHI patients showed
little to no decrease in CD8 counts and persistent CD8
elevation.27,31 In addition, our sensitivity analyses adjusting
for CD4/CD8 ratio 3 months after ART initiation were similar
to the main results, suggesting that CD4/CD8 ratio recovery
in AHI was more likely attributable to ART. There is
variability in the literature, however, in the reported incidence
of normalized ratios, with 2-year estimates ranging from
approximately 30%–65%, which may be explained by
different study definitions and approaches.27,28,30 Acute/
primary HIV has been variably defined using seroconversion
dates, Fiebig staging, and retroviral syndrome, with treatment
initiation windows ranging from 1 to 6 months. Normalized
CD4/CD8 ratios have been defined using a threshold of 0.9,
1, or 1.2 and either 1 or 2 measurements. Some investigators
excluded patients who had limited follow-up or never
achieved viral suppression. One study used competing risk
analysis, which did not censor patients after virologic failure
or loss to follow-up and could have resulted in lower
proportions.30 Our study’s strict definition of early treatment
(,120 days of estimated infection, with a median of 43 days
among AHI patients) may explain our 2-year ratio normali-
zation of 70%.
In CHI patients, CD4/CD8 ratio recovery rates were
low in our study as in previous works,17,26,30,32–35 partly
due to persistently elevated CD8 counts. Even CHI patients
initiating ART with CD4 .350 attained normal CD4
counts after 3 years but not normal CD8 counts or CD4/
CD8 ratios. These trends are consistent with other cohort
studies,27,36 and with a cross-sectional analysis showing
that CD8, not CD4, differences drive CD4/CD8 ratio
variability in patients with long-term suppression.33 Earlier
ART in CHI improves CD4 recovery,24,37–39 but its impact
on CD4/CD8 ratio normalization may be more nuanced. In
our study, after stratifying or adjusting for pre-ART CD4/
CD8 ratio, there was little difference in ratio normalization
rates by CD4 count among CHI, but a higher CD4/CD8
ratio at baseline remained a significant predictor of
normalization. One study reported that pre-ART CD4
counts and CD4/CD8 ratios were jointly predictive of ratio
recovery in chronic patients, in models including both
variables.35 Other studies found both pre-ART CD4 and
CD8 counts were predictive of CD4/CD8 ratio recovery but
did not adjust for CD4/CD8 ratios.30,32,33,35 Our analyses
suggest that adjusting for CD4 and CD8 alone may not take
into account the level of immune dysfunction at ART
initiation because pre-ART CD4/CD8 ratio remained
strongly predictive of ratio normalization. After established
immune dysfunction as indicated by a low ratio, pre-ART
CD4 count may have only a modest effect on CD4/CD8
ratio improvements, with slow and rare ratio recovery
taking place as CD4 counts increase slowly over time,
while CD8 counts remain persistently elevated. Further-
more, CD8 cell dynamics observed in our study (Fig. 3B)
may generate hypotheses and warrant further research
because CD8 trajectories seem to differ not only by AHI
versus CHI status but also by baseline immunosuppression,
in contrast to more parallel CD4 changes.
outcome or censoring by 3 months after ART (n = 29 for AHI 
and n = 502 for CHI), using this time point as the new 
baseline. In fully adjusted models including CD4/CD8 ratio at 
3 months, AHI patients had a normalization HR of 5.06 (95%
CI: 3.21 to 7.97) compared to all CHI patients, and 2.34 (95%
CI: 1.37 to 3.98) compared to CHI with CD4 .350. In an 
analysis censoring patients at a less strict definition of 
virologic failure (any HIV RNA $400 copies/mL after 90 
days of ART), estimates were also similar to the main 
findings. In analyses including baseline CD8 count instead 
of baseline CD4/CD8 ratio in fully adjusted models, estimates 
were similar to partially adjusted analyses.
CD4, CD8, and CD4/CD8 Ratio Trajectories
Compared to CHI patients with baseline CD4 ,200, 
the CD4 counts and CD4/CD8 ratios of AHI patients 
remained higher at every examined time point (Figs. 3A, C, 
all P , 0.05). AHI patients also had higher baseline CD8 
counts than CHI with CD4 ,200 but experienced a rapid 
drop in CD8 counts after starting ART and maintained levels 
lower than this CHI group after 2 years but not significantly 
lower after 3 years (Fig. 3B, P , 0.05 and P = 0.06, 
respectively). These changes were reflected in the CD4/CD8 
ratio that quickly rose by 3 months after baseline among AHI 
patients, reaching a normal median 6 months after baseline. 
CHI patients with CD4 .350 had baseline CD4, CD8, and 
CD4/CD8 ratio comparable to AHI patients (median 483 vs. 
454, 1064 vs. 1134, and 0.5 vs. 0.4, respectively). Three years 
after baseline, these CHI patients’ CD4 cell counts increased 
to levels comparable to AHI counts (median 767 vs. 721, 
P = 0.13), but CD8 counts remained elevated (median 779 vs. 
634, P , 0.05), and CD4/CD8 ratios were lower, although 
not with statistical significance (0.9 vs. 1.2, P = 0.08).
DISCUSSION
In this study, patients who initiated ART during AHI 
within 4 months of infection were more likely to achieve 
a normal CD4/CD8 ratio than patients who were chronically 
infected at ART start. Patients with AHI also had the shortest 
time to normalization when compared to CHI patients, 
regardless of CHI patients’ CD4 counts and CD4/CD8 ratios 
at baseline. Among CHI patients, those with higher baseline 
CD4 and CD4/CD8 ratios fared better in time to normaliza-
tion. However, even CHI patients with baseline CD4 counts 
.350 did not achieve normal CD4/CD8 ratio to the extent of 
AHI patients. After 3 years of therapy, CHI patients with 
baseline CD4 .350 reached CD4 counts comparable to those 
of AHI patients, but their CD8 counts remained elevated, 
whereas AHI patients experienced a rapid drop in CD8 cells 
in the first few months of ART.
Our findings on the impact of ART initiation very early 
in HIV infection on immune recovery are consistent with 
earlier observational studies showing that ART during acute 
or primary HIV leads to faster and higher rates of CD4/CD8 
ratio recovery.17,26–30 A primary HIV infection study also 
reported the dual role of rapid CD4 rise and CD8 drop in 
CD4/CD8 ratio normalization after ART initiation.27
treated patients to chronic patients at various stages of
immunosuppression, demonstrating that the role of AHI
may go beyond CD4 count levels at ART initiation. This
study also combines time-to-event analyses for CD4/CD8
ratio normalization with longitudinal examination of T-cell
and ratio distributions, providing insight into immune system
changes in addition to factors associated with immune
recovery. In addition, CD4/CD8 ratio measurement frequency
was very similar across groups, limiting the potential for bias.
However, our results are limited by relatively small sample
sizes, which reduced statistical power when stratifying
patients according to both CD4 and CD4/CD8 ratio at
baseline. Moreover, we were not able to adjust for additional
variables that may affect immune activation such as coinfec-
tion with cytomegalovirus or tobacco smoking.33,60,61 Finally,
our study included patients from only one geographic area
and may not be generalizable to other regions, although the
UCHCC is representative of the southeastern US HIV
epidemic.25
In summary, our study showed that initiating ART
within a few weeks of HIV infection is associated with
substantially higher rates and shorter time to CD4/CD8 ratio
normalization, compared to patients initiating treatment with
CHI. In addition, although initiating therapy with a higher
CD4 count during CHI may lead to better CD4 recovery, it
may not be associated with CD4/CD8 ratio normalization
when CD8 counts are elevated and ratios are low at initiation.
This work further underscores the importance of diagnosing
and treating HIV early, because immune dysfunction caused
by HIV disease progression, as measured by the CD4/CD8
ratio, may not be reversible for patients with longer delays.
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Few recent studies have examined demographic factors 
associated with CD4/CD8 ratio recovery during ART in 
either AHI or CHI. Some studies have reported better ratio 
recovery for female patients,30,40,41 and one study for white 
patients.40 We found a similar effect of female sex but no 
association with race. Younger age has generally been 
associated with better ratio recovery.35,40–42 In our study, 
younger age was associated with shorter time to normaliza-
tion in unadjusted analyses, but longer time to normalization 
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